Comparing Patient-Reported Outcomes Among Anti-TNF-Experienced Patients with Crohn’s Disease Initiating Vedolizumab Versus Ustekinumab
Kappelman M, Lewis J, Zhang X, Lin F, Weisbein L, Chen W, Burris J, Dorand J, Parlett L, Haynes K, Nair V, Kaul A, Dobes A, Long M. Comparing Patient-Reported Outcomes Among Anti-TNF-Experienced Patients with Crohn’s Disease Initiating Vedolizumab Versus Ustekinumab. Digestive Diseases And Sciences 2023, 68: 3413-3420. PMID: 37115362, DOI: 10.1007/s10620-023-07942-0.Peer-Reviewed Original ResearchConceptsShort Crohn's Disease Activity IndexDisease activity indexCrohn's diseasePain interferenceCorticosteroid useTreatment persistenceSecondary outcomesAnti-tumor necrosis factor therapyOutcomes Measurement Information System (PROMIS) domainsCrohn's Disease Activity IndexEffectiveness of vedolizumabHigher corticosteroid useLower treatment persistenceNecrosis factor therapyCo-primary outcomesPatient-reported outcomesInternet-based cohort studyLogistic regression modelsIBD PartnersCohort studyExperienced patientsFactor therapyPrimary outcomeBiological therapySteroid use